BHR-100 Approval Status
- FDA approved: No
- Brand name: BHR-100
- Generic name: progesterone
- Dosage form: Intravenous Infusion
- Company: BHR Pharma, LLC
- Treatment for: Head Injury
BHR-100 is a proprietary intravenous progesterone infusion product in development as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients.
Development Status and FDA Approval Process for BHR-100
|Sep 3, 2013||BHR Pharma Announces SyNAPSe® Trial Completes Patient Enrollment|
|Dec 8, 2009||BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.